Looks like the international competition is hotting up folks. So it’s likely Colostat won’t be the first, second or even third blood test globally to be used as an early screening tool for colorectal cancer. Several are expected to be released in various parts of the world in 2019. Is this what’s dragging our SP down? At the end of the day I guess it’s a big world with a lot of arses, and the quality, ease and price of the test will be big drivers for who dominates. Roll on reagent development and clinical trials ASAP!
https://www.japantimes.co.jp/news/2018/11/24/business/corporate-business/japans-shimadzu-corp-commercialize-new-blood-test-detect-early-stage-colon-cancer/#.XAUUqIp_WhA
Looks like the international competition is hotting up folks. So...
Add RHY (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
11.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $15.41M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 5969 | 13.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 11.0¢ | 5500 | 1 |
View Market Depth
| Last trade - 16.16pm 18/11/2024 (20 minute delay) ? |
| RHY (ASX) Chart |
Day chart unavailable
